Equities analysts expect United Therapeutics Corporation (NASDAQ:UTHR) to post $3.41 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for United Therapeutics Corporation’s earnings, with the lowest EPS estimate coming in at $1.48 and the highest estimate coming in at $4.09. United Therapeutics Corporation reported earnings per share of $2.43 during the same quarter last year, which suggests a positive year-over-year growth rate of 40.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that United Therapeutics Corporation will report full year earnings of $11.92 per share for the current year, with EPS estimates ranging from $10.39 to $13.15. For the next year, analysts anticipate that the company will post earnings of $11.60 per share, with EPS estimates ranging from $10.73 to $13.16. Zacks’ EPS calculations are an average based on a survey of research firms that cover United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.23 EPS.

Several brokerages have recently commented on UTHR. Zacks Investment Research lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. BidaskClub lowered United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, October 26th. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $132.82.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,235 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $131.95, for a total value of $162,958.25. Following the completion of the sale, the chief executive officer now owns 2,304 shares in the company, valued at $304,012.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 2,176 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the completion of the sale, the chief executive officer now owns 3,245 shares of the company’s stock, valued at approximately $412,471.95. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,389 shares of company stock valued at $2,287,452. 7.80% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in UTHR. Wells Fargo & Company MN lifted its position in United Therapeutics Corporation by 144.0% in the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after purchasing an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. lifted its position in United Therapeutics Corporation by 308.6% in the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after purchasing an additional 378,002 shares during the last quarter. Renaissance Technologies LLC lifted its position in United Therapeutics Corporation by 65.5% in the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after purchasing an additional 331,400 shares during the last quarter. Schroder Investment Management Group lifted its position in United Therapeutics Corporation by 42.8% in the second quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock valued at $143,359,000 after purchasing an additional 327,360 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in United Therapeutics Corporation by 58.0% in the second quarter. Dimensional Fund Advisors LP now owns 726,760 shares of the biotechnology company’s stock valued at $94,286,000 after purchasing an additional 266,790 shares during the last quarter.

Shares of United Therapeutics Corporation (UTHR) opened at $120.95 on Friday. The company has a market cap of $5,137.79, a PE ratio of 10.48 and a beta of 1.38.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/04/analysts-expect-united-therapeutics-corporation-uthr-will-announce-earnings-of-3-41-per-share.html.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.